NASDAQ:CYTO Altamira Therapeutics (CYTO) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free CYTO Stock Alerts $1.61 -0.01 (-0.62%) (As of 02:36 PM ET) Add Compare Share Share Today's Range$1.57▼$1.6750-Day Range$1.40▼$2.4352-Week Range$1.35▼$28.40Volume30,442 shsAverage Volume932,047 shsMarket Capitalization$2.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Altamira Therapeutics alerts: Email Address Altamira Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.26) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Altamira Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.87% of the float of Altamira Therapeutics has been sold short.Short Interest Ratio / Days to CoverAltamira Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altamira Therapeutics has recently decreased by 80.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAltamira Therapeutics does not currently pay a dividend.Dividend GrowthAltamira Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYTO. Previous Next 1.9 News and Social Media Coverage News SentimentAltamira Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Altamira Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CYTO on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Altamira Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altamira Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.03% of the stock of Altamira Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.91% of the stock of Altamira Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Altamira Therapeutics are expected to grow in the coming year, from ($4.26) to ($3.02) per share.Price to Book Value per Share RatioAltamira Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Altamira Therapeutics Stock (NASDAQ:CYTO)Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Read More CYTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTO Stock News HeadlinesMay 2, 2024 | americanbankingnews.comAltamira Therapeutics (NASDAQ:CYTO) Trading 3.2% Higher May 1, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 24, 2024 | msn.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 15, 2024 | finance.yahoo.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 10, 2024 | finance.yahoo.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 4, 2024 | globenewswire.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024March 26, 2024 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 26, 2024 | markets.businessinsider.comCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 25, 2024 | msn.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | globenewswire.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalJanuary 24, 2024 | marketwatch.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | msn.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | finance.yahoo.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 8, 2024 | finance.yahoo.comAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitDecember 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 11, 2023 | msn.comAltamira shares sink over 40% on corporate, stock split updatesDecember 11, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Down 50% TodayDecember 11, 2023 | finance.yahoo.comAltamira Therapeutics Provides Investor and Business UpdateDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thSee More Headlines Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)7/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales7.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.36Miscellaneous Outstanding Shares1,578,000Free Float1,372,000Market Cap$2.56 million OptionableNot Optionable Beta1.79 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Thomas Meyer Ph.D. (Age 56)Founder, President, Chairman, CEO & MD Comp: $552.7kDr. Covadonga Paneda (Age 50)Chief Operating Officer Dr. Samuel A. Wickline M.D. (Age 71)Chief Scientific Adviser Key CompetitorsSonoma PharmaceuticalsNASDAQ:SNOAAllarity TherapeuticsNASDAQ:ALLRCohBarNASDAQ:CWBRMustang BioNASDAQ:MBIOSalarius PharmaceuticalsNASDAQ:SLRXView All Competitors CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed in 2024? Altamira Therapeutics' stock was trading at $3.48 on January 1st, 2024. Since then, CYTO shares have decreased by 53.7% and is now trading at $1.61. View the best growth stocks for 2024 here. Are investors shorting Altamira Therapeutics? Altamira Therapeutics saw a decrease in short interest in April. As of April 15th, there was short interest totaling 86,700 shares, a decrease of 80.5% from the March 31st total of 444,500 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.9% of the shares of the company are sold short. View Altamira Therapeutics' Short Interest. When is Altamira Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our CYTO earnings forecast. When did Altamira Therapeutics' stock split? Altamira Therapeutics's stock reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsThe biggest energy story ever? Porter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
